NASDAQ · QDELHealthcareDiagnostics

QuidelOrtho financials

$10.60−2.17%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 28
FY24
Dec 29
FY23
Dec 31
FY22
Jan 1
Revenue$2.73B$2.78B$3.00B$3.27B
Gross profit$1.27B$1.29B$1.50B$1.94B
Gross margin46.7%46.2%49.9%59.3%
Operating income-$919.2M-$1.96B$139.1M$979.7M
Net income-$1.13B-$2.05B-$10.1M$548.7M
Net margin−41.5%−73.7%−0.3%16.8%
Diluted EPS$-16.69$-30.54$-0.15$9.56
EBITDA$496.8M$499.2M$714.2M$1.27B
Operating cash flow$105.2M$83.0M$280.2M$885.3M
Free cash flow-$83.0M-$112.1M$70.9M$744.4M
Diluted shares67.8M67.2M66.8M57.4M

Balance sheet

Period endDec 28Dec 29Dec 31Jan 1
Cash & equivalents$169.8M$98.3M$118.9M$292.9M
Short-term investments$0.00$0.00$48.4M$52.1M
Total debt$2.65B$2.48B$2.41B$2.64B
Total assets$5.77B$6.42B$8.56B$8.86B
Total liabilities$3.85B$3.44B$3.56B$3.92B
Shareholders' equity$1.92B$2.98B$5.01B$4.93B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology